Search result for "Solr search content"
Search Result for "Bladder Cancer"
Cancer Treatments
Cancer Treatments
provider
Dharam Kaushik, M.D. Urology Oncology, Urology
provider
Furkan Dursun, MD Genitourinary Surgery, Genitourinary Oncology
provider
John Sarantopoulos, MD Medical Oncology, Internal Medicine
Our Cancer Programs
Our Cancer Programs
Clinical Trial
A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with advanced unresectable and/or metastatic immune checkpoint inhibitor (ICI) refractory solid tumors or ICI naive MSS/MSI-low solid tumors (CT
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors